Boehringer Ingelheim signed a global deal worth up to $478 million for a preclinical antibody program from Immunitas Therapeutics. The antibody is designed to selectively eliminate pathogenic cells at inflammation sites rather than broadly suppress individual cytokine signals, targeting chronic inflammatory and autoimmune diseases. Boehringer will handle full worldwide development, manufacturing, and commercialization, with Immunitas set to receive an undisclosed upfront payment plus eligibility for development, regulatory, and commercial milestones. Immunitas says partnering with Boehringer will move the candidate into clinical development with global immunology expertise.